We are live on ! Find out more
NLVP

New Leaf Venture Partners Portfolio holdings

AUM $43M
1-Year Est. Return 25.55%
This Fund
S&P 500
This Quarter Est. Return
+5.87%
1 Year Est. Return
-25.55%
3 Year Est. Return
+17.13%
5 Year Est. Return
+114.46%
10 Year Est. Return
+1,011.57%
AUM
$550M
AUM Growth
+$135M
Cap. Flow
+$121M
Cap. Flow %
22.08%
Top 10 Hldgs %
91.76%
Holding
21
New
6
Increased
3
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$74.1M
2
ARVN icon
Arvinas
ARVN
+$37.6M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$4.98M
4
CMRX
Chimerix, Inc.
CMRX
+$4.26M
5
TARA icon
Protara Therapeutics
TARA
+$3.46M

Top Sells

Rank Stock Value
1
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$4.02M
2
AFMD
Affimed
AFMD
+$1.27M
3
WVE icon
Wave Life Sciences
WVE
+$361K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCPH
1
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$159M 28.92%
4,104,140
– –
APTX
2
DELISTED
Aptinyx Inc. Common Stock
APTX
$95.3M 17.34%
3,290,079
– –
PRNB
3
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$76.7M 13.96%
+2,625,713
New +$74.1M
STIM icon
4
Neuronetics
STIM
$123M
$49.5M 9%
1,543,115
– –
ARVN icon
5
Arvinas
ARVN
$524M
$38.5M 7.01%
+2,283,048
New +$37.6M
WVE icon
6
Wave Life Sciences
WVE
$1.12B
$21.3M 3.87%
425,429
-8,000
-2% -$361K
CRSP icon
7
CRISPR Therapeutics
CRSP
$4.61B
$19.7M 3.59%
444,708
– –
COGT icon
8
Cogent Biosciences
COGT
$6.74B
$18.5M 3.37%
448,886
– –
OBSV
9
DELISTED
ObsEva SA Ordinary Shares
OBSV
$16.2M 2.95%
900,501
+10,000
+1% +$147K
ITRM
10
DELISTED
Iterum Therapeutics
ITRM
$9.65M 1.76%
97,087
– –
TECX
11
Tectonic Therapeutic
TECX
$577M
$8.94M 1.63%
14,363
+1,863
+15% +$826K
SRRA
12
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$8.54M 1.55%
125,511
– –
AFMD
13
DELISTED
Affimed
AFMD
$7.83M 1.42%
180,000
-45,000
-20% -$1.27M
CRNX icon
14
Crinetics Pharmaceuticals
CRNX
$8.87B
$4.8M 0.87%
+167,700
New +$4.98M
CMRX
15
DELISTED
Chimerix, Inc.
CMRX
$3.89M 0.71%
+1,000,000
New +$4.26M
ARAV
16
DELISTED
Aravive, Inc. Common Stock
ARAV
$3.47M 0.63%
413,067
+38,567
+10% +$406K
TARA icon
17
Protara Therapeutics
TARA
$225M
$2.92M 0.53%
+37,500
New +$3.46M
PDSB icon
18
PDS Biotechnology
PDSB
$38.4M
$1.92M 0.35%
117,243
– –
NERV icon
19
Minerva Neurosciences
NERV
$196M
$1.63M 0.3%
+16,250
New +$1.22M
AVEO
20
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$1.33M 0.24%
40,212
– –
OXFD
21
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
– –
-311,660
Closed -$4.02M

Similar funds

BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

New Leaf Venture Partners's Q3 2018 Portfolio in Review

As of Q3 2018, New Leaf Venture Partners held 21 positions worth $550M, up 33% from $414M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

New Leaf Venture Partners deployed $121M of net new capital in Q3 2018, opening 6 new positions and adding to 3 existing holdings. Its largest new stake was Principia Biopharma Inc. Common Stock: 2,625,713 shares worth $76.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Affimed, an estimated $1.27M trimmed.

  • New Leaf Venture Partners's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 2,625,713 shares worth $76.7M.
  • New Leaf Venture Partners added most to Tectonic Therapeutic in Q3 2018, an estimated $826K increase.
  • New Leaf Venture Partners's biggest Q3 2018 reduction was Affimed, cutting an estimated $1.27M.
  • New Leaf Venture Partners fully exited Oxford Immunotec Global PLC Ordinary Shares in Q3 2018, selling an estimated $4.02M.
  • New Leaf Venture Partners's ten largest holdings make up 92% of its $550M portfolio in Q3 2018.
  • New Leaf Venture Partners opened 6 new positions and closed 1 in Q3 2018.
  • New Leaf Venture Partners's portfolio value rose 33% quarter-over-quarter to $550M.

Based on New Leaf Venture Partners's 13F filing for Q3 2018, filed 13 Nov 2018.